Inhibikase Therapeutics IKT
NASDAQ IKT
$1.62 +0.07 (+4.45%)
As of: Nov 11, 2026 · 10:45 AM EST

Inhibikase Therapeutics (IKT) Return on Equity [ROE] (2020 - 2026)

Updated

Inhibikase Therapeutics (IKT) posted Return on Equity [ROE] of -40.78% for Q2 2026, up 12.53 percentage points from -53.31% a year earlier but down 8.35 percentage points from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Return on Equity [ROE] (2020 - 2026) Analysis & Trends

For FY2025, Inhibikase Therapeutics' Return on Equity [ROE] came in at -38.82%, up 15.20 percentage points from FY2024.

  • Annual Return on Equity [ROE] shows a four-year change of +22.53 percentage points (FY2021 to FY2025).
  • In prior years, Inhibikase Therapeutics' Return on Equity [ROE] was -54.02% in FY2024 (+71.49 pp), -125.51% in FY2023 (-64.52 pp), -60.99% in FY2022 (+0.37 pp) and -61.35% in FY2021.
  • Quarterly Return on Equity [ROE] has run from a low of -878.83% in Q3 2024 to a high of -24.28% in Q3 2021 over five years.
  • On a year-over-year basis, Return on Equity [ROE] has increased in each of the last seven quarters, with an average year-over-year change of +79.44 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Equity [ROE] in the past five years was Q3 2025, with a gain of 811.98 percentage points; the weakest was Q3 2024, with a drop of 762.71 percentage points.
  • According to Business Quant data, Return on Equity [ROE] for the three prior quarters was -32.43% (Q1 2026), -42.29% (Q4 2025) and -66.85% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Inhibikase Therapeutics 281.11 Mn -420.36 Mn - -11,479,904.39%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -11,479,904.39%
Jun 30, 2026 -12,237,297.52%
Mar 31, 2026 -5,824,871.44%
Dec 31, 2025 -8,069,535.00%
Sep 30, 2025 -12,968,171.52%
Jun 30, 2025 -11,964,375.61%
Mar 31, 2025 -5,491,635.97%
Dec 31, 2024 -10,513,210.12%
Sep 30, 2024 -217,204,713.76%
Jun 30, 2024 -83,529,354.48%
Mar 31, 2024 -218.18%
Dec 31, 2023 -147.20%
Sep 30, 2023 -111.11%
Jun 30, 2023 -85.06%
Mar 31, 2023 -76.53%
Dec 31, 2022 -77.75%
Sep 30, 2022 -68.78%
Jun 30, 2022 -59.18%
Mar 31, 2022 -46.36%
Dec 31, 2021 -36.25%
API Access

Inhibikase Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=IKT&period=max&api_key=YOUR_API_KEY